Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
Conditions
Interventions
Deucravacitinib
Placebo
Locations
28
United States
Local Institution - 0016
Santa Monica, California, United States
Local Institution - 0036
New Haven, Connecticut, United States
Local Institution - 0018
Tampa, Florida, United States
Local Institution - 0023
Clinton Township, Michigan, United States
Local Institution - 0024
New York, New York, United States
Local Institution - 0019
Chapel Hill, North Carolina, United States
Start Date
November 8, 2022
Primary Completion Date
January 6, 2024
Completion Date
May 16, 2024
Last Updated
May 31, 2025
NCT07029711
NCT06826196
NCT06562270
NCT07133308
NCT06327581
NCT07023302
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions